Suven Life Sciences Starts Phase I Trial for Alzheimer’s Drug

by Kathy Jones on  November 4, 2014 at 8:47 PM Clinical Trials News
RSS Email Print This Page Comment bookmark
Font : A-A+

Hyderabad-based Suven Life Sciences announced that it has started Phase I clinical trial of its experimental drug for treating Alzheimer's and schizophrenia.
 Suven Life Sciences Starts Phase I Trial for Alzheimer’s Drug
Suven Life Sciences Starts Phase I Trial for Alzheimer’s Drug

The company revealed that it has submitted the data for Investigational New Drug Application with the US Food and Drug Administration after wrapping up all the pre-clinical, safety and early toxicological studies.

The approval will provide it with the authorization to conduct the Phase 1 clinical trial of the investigational drug, which the company claims to be a 'potent, selective, brain penetrant and orally active Histamine H3 antagonist' in treating the cognitive effects associated with Alzheimer's and schizophrenia.

"We are very pleased that the second compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia with high unmet medical need which has huge market potential globally", The CEO of Suven, Vekat Jasti said.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Constipation Signature Drug Toxicity Irritable Bowel Syndrome 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...